STVN

Stevanato Group S.p.A.

15.91

USD

STVN Earnings Reports

Positive Surprise Ratio

STVN beat 12 of 19 last estimates.

63%

Next Report

Date of Next Report

May 01, 2026

Estimate for Q1 26 (Revenue/ EPS)

$280.24M

$0.11

Implied change from Q4 25 (Revenue/ EPS)

-19.10%

-38.89%

Implied change from Q1 25 (Revenue/ EPS)

+9.21%

+10.00%

Stevanato Group S.p.A. earnings per share and revenue

On Mar 04, 2026, STVN reported earnings of 0.18 USD per share (EPS) for Q4 25, beating the estimate of 0.17 USD, resulting in a 4.55% surprise. Revenue reached 346.41 million, compared to an expected 339.67 million, with a 1.99% difference. The market reacted with a +18.81% price change (close before vs. close after earnings).

Looking ahead to Q1 26, 10 analysts forecast an EPS of 0.11 USD, with revenue projected to reach 280.24 million USD, implying an decrease of -38.89% EPS, and decrease of -19.10% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

Dyne Therapeutics, Inc. Common Stock

Report Date

Mar 02, 2026 For Q4 25

Estimate

-$0.77

Actual

-$0.76

Surprise

+2.28%

Harrow, Inc. Common Stock

Report Date

Mar 02, 2026 For Q4 25

Estimate

$0.37

Actual

$0.26

Surprise

-30.87%

Amylyx Pharmaceuticals, Inc. Common Stock

Report Date

Mar 03, 2026 For Q4 25

Estimate

-$0.36

Actual

-$0.30

Surprise

+18.50%

Bioventus Inc. Class A Common Stock

Report Date

Mar 05, 2026 For Q4 25

Estimate

$0.21

Actual

$0.24

Surprise

+9.69%

Altimmune, Inc. Common Stock

Report Date

Mar 05, 2026 For Q4 25

Estimate

-$0.24

Actual

-$0.27

Surprise

-10.16%

Aquestive Therapeutics, Inc. Common Stock

Report Date

Mar 04, 2026 For Q4 25

Estimate

-$0.13

Actual

-$0.26

Surprise

-92.31%

OmniAb, Inc. Common Stock

Report Date

Mar 04, 2026 For Q4 25

Estimate

-$0.09

Actual

-$0.11

Surprise

-21.82%

Profound Medical Corp. Common Stock

Report Date

Mar 05, 2026 For Q4 25

Estimate

-$0.26

Actual

-$0.27

Surprise

-0.26%

MediWound Ltd.

Report Date

Mar 05, 2026 For Q4 25

Estimate

-$0.64

Actual

-$0.56

Surprise

+13.08%

Cumberland Pharmaceuticals Inc

Report Date

Mar 03, 2026 For Q4 25

Estimate

Actual

-$0.01

Surprise

FAQ

What were Stevanato Group S.p.A.'s earnings and revenue for the latest quarter Q4 2025?

For Q4 2025, Stevanato Group S.p.A. reported EPS of $0.18, beating estimates by 4.55%, and revenue of $346.41M, 1.99% above expectations.

How did the market react to Stevanato Group S.p.A.'s Q4 2025 earnings?

The stock price moved up 18.81%, changed from $14.73 before the earnings release to $17.50 the day after.

When is Stevanato Group S.p.A. expected to report next?

The next earning report is scheduled for May 01, 2026.

What are the forecasts for Stevanato Group S.p.A.'s next earnings report?

Based on 10 analysts, Stevanato Group S.p.A. is expected to report EPS of $0.11 and revenue of $280.24M for Q1 2026.

Which companies are reporting earnings today?

Check FXEmpire's Earnings Calendar for today's list of reporting companies.